Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 13/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351982 | 0.91 | PDGFRB (0.59) | PDGFRBLIMK2KIT | |
| SCHEMBL4362468 | 0.90 | PDGFRB (0.62) | PDGFRBPDGFRALIMK2KIT | |
| SCHEMBL4360205 | 0.86 | PDGFRB (0.65) | PDGFRBPDGFRAKIT | |
| SCHEMBL4358579 | 0.85 | PI4KB (0.58) | PDGFRBLIMK2SMN1; SMN2NLRP3P2RY12 | |
| SCHEMBL4358653 | 0.85 | PDGFRB (0.67) | PDGFRBPDGFRALIMK2KIT | |
| SCHEMBL4355558 | 0.84 | SMN1; SMN2 (0.52) | PDGFRBPDGFRALIMK2AKT1SMN1; SMN2 | |
| SCHEMBL3933256 | 0.82 | LIMK2 (0.60) | PDGFRBPDGFRALIMK2SMN1; SMN2NLRP3 | |
| SCHEMBL4358571 | 0.81 | AKT1 (0.65) | PDGFRBPDGFRAAKT1 | |
| SCHEMBL2923409 | 0.80 | PDGFRB (0.81) | PDGFRBPDGFRAKIT | |
| SCHEMBL8149578 | 0.78 | LIMK2 (0.55) | PDGFRBLIMK2KITP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | PDGFRB 2755/4885PDGFRA 2611/4885LIMK2 3737/4885 |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | PDGFRB 2532/4885PDGFRA 2211/4885LIMK2 4163/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | PDGFRB 2642/4885PDGFRA 2341/4885LIMK2 4253/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | PDGFRB 2642/4885PDGFRA 2341/4885LIMK2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.